Core Viewpoint - The company, originally established in 2008 as a leading cleanroom system integrator, is expanding its business from medical applications to laboratory integration and electronic cleanroom services, aiming to create a second growth curve and enhance its market position in the semiconductor ecosystem [1][2]. Group 1: Business Expansion and Market Position - The company has transitioned from focusing solely on medical cleanrooms to include laboratory integration and electronic cleanroom services, having served over 800 clients including public hospitals and industrial electronics firms [1]. - The company announced a name change from "Huakang Medical" to "Huakang Clean" in March 2025, and plans to issue 750 million yuan in convertible bonds to support new business initiatives [1]. - A joint venture named "Wuhan Guanggu Huafeng Operation Technology Co., Ltd." was established with partners to strengthen future growth in the cleanroom technology sector [1]. Group 2: Market Dynamics and Financial Performance - The medical purification system market in China is valued at approximately 31.27 billion yuan annually, with the company holding orders worth 2.753 billion yuan for 2024, indicating a robust order book [2]. - The company has achieved positive operating cash flow of 150 million yuan in 2024, indicating a balance between orders and cash flow, which supports sustainable growth in its core business [2]. - The electronic cleanroom sector, which accounted for 54% of the cleanroom industry in 2022, is expected to see continued demand growth, with the company entering this market through strategic partnerships and service capabilities [2]. Group 3: Revenue and Profit Forecast - Revenue projections for the company from 2025 to 2027 are estimated at 2.8 billion, 3.6 billion, and 4.8 billion yuan, representing year-on-year growth rates of 61%, 32%, and 33% respectively [3]. - The net profit attributable to the parent company is forecasted to be 170 million, 220 million, and 300 million yuan for the same period, with growth rates of 156%, 30%, and 35% respectively [3]. - The company is expected to maintain a solid growth trajectory based on its established experience in the medical cleanroom sector and its expansion into the semiconductor cleanroom market [3].

Investment Rating - The report gives a "Buy" rating for the company, Huakang Clean [5]. Core Views - Huakang Clean is a leading cleanroom system integrator in the medical sector, expanding into the electronic cleanroom market, which is experiencing high demand [3][5]. - The company has a solid order backlog in the medical sector, with a total order value of 2.753 billion yuan for 2024, indicating stable growth prospects [4][5]. - The electronic cleanroom segment is expected to become a significant growth driver, with the market for electronic cleanrooms projected to exceed 1 trillion yuan in 2022 [5][6]. Summary by Sections Company Overview - Established in 2008, Huakang Clean has evolved from a medical cleanroom service provider to include laboratory integration and electronic cleanroom services, serving over 800 clients [3][4]. - The company rebranded from "Huakang Medical" to "Huakang Clean" in March 2025 to better reflect its focus on clean technology [3]. Market Potential - The cleanroom market in China is projected to reach approximately 312.68 billion yuan annually, driven by the increasing demand for clean surgical rooms and system upgrades [4][48]. - The electronic cleanroom market, which accounted for 54% of the cleanroom industry in 2022, is expected to see continued growth due to rising semiconductor investments [5][56]. Financial Projections - Revenue forecasts for Huakang Clean are 2.755 billion yuan in 2025, 3.644 billion yuan in 2026, and 4.830 billion yuan in 2027, with expected growth rates of 61%, 32%, and 33% respectively [5][7]. - The net profit is projected to reach 171 million yuan in 2025, 222 million yuan in 2026, and 301 million yuan in 2027, reflecting growth rates of 156%, 30%, and 35% respectively [5][7]. Competitive Position - Huakang Clean holds a strong competitive position in the medical cleanroom sector, ranking among the top three in terms of bid amounts from 2017 to 2020 [48]. - The company has established a robust reputation and project experience, which enhances its ability to secure new contracts and expand its market share [71][79].

证券代码：301235 证券简称：华康洁净 公告编号：2025-063 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 4、中标单位：武汉华康世纪洁净科技股份有限公司 5、中标价格：60,239,413.05 元 6、工期：120 日历天 7、公示媒体：枣庄市公共资源交易中心（http://ggzy.zaozhuang.gov.cn） 8、公示期：2025 年 05 月 23 日至 2025 年 05 月 25 日 特别提示：本项目仍处于中标公示阶段，其获取中标通知书、签约等后续工 作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应的信 息披露义务。 公司于近日参与了"滕州市医养结合健康中心暨中心人民医院新院区项目共 享医疗综合楼特殊科室专项净化工程二标段"项目的投标，招标单位为山东德辰 康养投资管理有限公司。2025 年 5 月 23 日，枣庄市公共资源交易中心（ht ...

1、调整前回购股份价格上限：28.00 元/股（含）； | 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 关于2024年年度权益分派实施后调整回购股份价格上限 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 自本次利润分配预案披露之日起至权益分派股权登记日期间，公司总股本若因新 增股份上市、股权激励行权、股份回购等事项发生变化，公司将按照"现金分红总额 固定不变"的原则对分配比例进行调整。 公司 2024 年度权益分派股权登记日为 2025 年 5 月 28 日，除权除息日为 2025 年 5 月 29 日。具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn） 的《2024 年年度权益分派实施公告》（公告编号：2025-060）。 2、调整后回购股份价格上限：27.95 元/股（含）； 3、回购股份价格上限调整生效日期：2025 年 5 ...

证券代码：301235 证券简称：华康洁净 公告编号：2025-060 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 特别提示： 1、武汉华康世纪洁净科技股份有限公司（以下简称"公司"或"本公司"）通过 回购专用证券账户持有的公司股份 2,132,100 股不享有利润分配权利。因此，本次权 益分派将以公司现有总股本 105,600,000 股剔除已回购股份 2,132,100 股后的 103,467,900 股为基数，本次实际分红总额=实际参与现金分红的股本×分配比例 =103,467,900 股×0.5 元/10 股=5,173,395 元。 2、本次权益分派实施后，根据股票市值不变原则，实施权益分派前后公司总股本 保持不变。按照公司总股本折算每 10 股现金分红=本次实际现金分红总额/公司总股 本(含已回购股份)×10=5,173,395 元/105,600,000 股×10=0.489904 元(保留六位小 数，最后一位直接截取，不四舍五入)。本次权益分派实施后的除息除权参考价=除息 除权日前一交易日收盘价-按公司总股本折算每股现金分红=除息除权日前一交易日 收盘价-0. ...

| 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-062 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 关于2024年年度权益分派调整可转债转股价格 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）向不特定对象发行可 转换公司债券事项经中国证券监督管理委员会证监许可〔2024〕220 号同意注册，公司 于 2024 年 12 月 23 日向不特定对象发行了 750.00 万张可转换公司债券，每张面值 100 元，发行总额 75,000.00 万元。经深圳证券交易所同意，公司 75,000.00 万元可转换公 司债券于 2025 年 1 月 9 日起在深圳证券交易所挂牌交易，债券简称"华医转债"， 债券代码"123251"。"华医转债"转股的起止日期为 2025 年 6 月 27 日至 2030 年 12 月 22 日止（如遇法定节假日或休息日延至其后的第 1 个交易日；顺延期间付息款 ...

国联民生证券承销保荐有限公司 关于武汉华康世纪洁净科技股份有限公司 2024 年年度持续督导跟踪报告 | 保荐机构名称：国联民生证券承销保荐有限 | 被保荐公司简称： 华康洁净（301235） | | --- | --- | | 公司 | | | 保荐代表人姓名：胡向春 | 联系电话：027-87315078 | | 保荐代表人姓名：邓毅 | 联系电话：027-87315078 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但 不限于防止关联方占用公司资源的制度、募集资 | | | | 是 | | 金管理制度、内控制度、内部审计制度、关联交 | | | 易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 12 次 | | （2）公司募集资金 ...

保荐代表人签字： 国联民生证券承销保荐有限公司 关于武汉华康世纪洁净科技股份有限公司 2024年度持续督导定期现场检查报告 | 保荐人名称：国联民生证券承销保荐有限公司 被保荐公司简称：华康洁净 | | --- | | 保荐代表人姓名：胡向春 联系电话：027-87316818 | | 保荐代表人姓名：邓毅 联系电话：027-87316818 | | 现场检查人员姓名：胡向春、邓毅、张永言、夏思懿 | | 现场检查对应期间：2024年1月1日-2024年12月31日 | | 现场检查时间：2025年4月8日-5月19日 | | (一) 公司治理 是 否 不适用 | | 现场检查手段(包括但不限于本指引第三十三条所列)：（1）查阅公司章程和各项规章制度； | | （2）查阅公司股东大会、董事会、监事会议事规则等公司基本制度，查阅2024年历次股东 | | 大会、董事会及监事会决议及记录；（3）访谈公司相关部门人员，了解公司基本制度的执 | | 行情况，了解公司董事、监事和高级管理人员履行职务勤勉尽责情况及变动情况，了解控股 | | 股东、实际控制人遵守相关承诺的情况。 | | √ 1.公司章程和公司治理制度是否 ...

Key Points - The article highlights various significant announcements from companies, including revenue growth, investment projects, and share buybacks [1][2] Company Announcements - Baili Electric's revenue from related businesses in 2024 will account for less than 1% of the company's total revenue [1] - Taihe Co., Ltd. plans to invest up to $150 million in a pesticide and functional chemicals project in Egypt [1] - Huakang Clean is expected to win a bid for the renovation of the second inpatient building at West China Hospital of Sichuan University [1] - YTO Express reported a revenue of 5.755 billion yuan from express products in April, a year-on-year increase of 16.32% [1] - Shentong Express reported a revenue of 4.118 billion yuan from express services in April, a year-on-year increase of 16.39% [1] - Kangping Technology plans to acquire 100% equity of Souluke Electronics for 198 million yuan [1] - Hexing Packaging intends to repurchase shares worth between 50 million to 100 million yuan [1] - Guangxi Media's controlling shareholder and its concerted parties plan to reduce their holdings by no more than 1% [1] - Huading Co., Ltd. plans to reduce its holdings by no more than 3% [1] - Jingu Co., Ltd. received a notification from a leading global new energy vehicle company [1] - Wanrun New Energy signed a business cooperation agreement with CATL, expecting a total supply volume of approximately 1.3231 million tons [1][2] Investment Projects - Huaheng Biological plans to invest 320 million yuan in an "AI Precision Fermentation and Protein Engineering Shared Demonstration Project" [1] Share Buybacks - Kesi Technology plans to repurchase shares worth between 30 million to 50 million yuan [1] - Zhaoxun Media intends to repurchase 1.66% to 3.33% of its shares [2]

关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：301235 证券简称：华康洁净 公告编号：2025-059 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 5、投标报价：71,602,160.12 元 6、公示媒体：四川省公共资源交易信息网（https://ggzyjy.sc.gov.cn） 7、公示期：2025 年 05 月 20 日至 2025 年 05 月 26 日 二、预中标事项对公司业绩的影响 特别提示：本项目仍处于中标公示阶段，其获取中标通知书、签约等后续工 作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应的信 息披露义务。 公司于近日参与了"四川大学华西医院第二住院楼 10 层装修、诊疗环境装 修项目(11 至 13 层手术室装修)"项目的投标，招标单位为四川大学华西医院。 2025 年 5 月 19 日，四川省公共资源交易信息网（https://ggzyjy.sc.gov.cn） 发布了 ...